ASEAN Guidelines for Stability Process Validation Variation
Your HSA Gateway
ASEAN Common Technical Dossier (ACTD)
ASEAN Common Technical Requirements (ACTR)
Regional markets we support
Let's Navigate Your HSA Registration Success
Singapore remains a prime choice for pharmaceutical market entry, with clear strategic business advantages.
Singapore is a prime choice for pharmaceutical companies to register their products due to its strategic location and stable business environment, making it an attractive destination for pharmaceutical companies seeking to register and commercialize their products in the Asia-Pacific region.
Key Singapore Benefits
The Health Sciences Authority (HSA) upholds international standards with a robust regulatory framework, ensuring swift and reliable product reviews with efficient approval processes.
Key points
Strategic Asia-Pacific location and regional hub status
Stable political and economic environment
Strong intellectual property protection
Attractive government incentives for pharmaceutical businesses
HSA Regulatory Advantages
Committed to timely reviews of product registrations
Adherence to global standards facilitates smoother registration processes
Recognition of approvals from reputable authorities (U.S. FDA, European EMA)
Enables companies to bring products to market more quickly compared to other jurisdictions
Attractive Tax Environment
Singapore is also known for its attractive tax system that benefits pharmaceutical companies:
Do not let regulatory complexity delay your Singapore market entry. Our Singapore-based regulatory experts, with deep HSA knowledge and proven track record, are ready to accelerate your pharmaceutical registration and market access in this strategic Asia-Pacific hub.
Contact us today to discuss how our Singapore expertise can accelerate your pharmaceutical market success.
Key points
Low corporate tax rate structure
Tax incentives for specific industries (including trading and logistics)
Extensive network of Double Taxation Agreements (DTAs) with numerous countries
Relatively low Goods and Services Tax (GST)
Appeal for international trade and business operations
Our Experiences in Singapore
For more than fifteen years we have steered New Drug Applications, generics, biologics, biosimilars, vaccines, cosmetics, health supplements, and medical devices through HSA—always with a clear path from classification to post-approval life.
That depth shows in the numbers: more than thirty NDA submissions in Singapore alone, spanning innovators and specialty portfolios that need careful pathway design, not a one-size dossier dump.
Singapore delivery at a glance
- 15+ years of hands-on local HSA experience across product classes
- More than 30 NDA submissions filed in Singapore, including biologics and specialty portfolios
- Live PRISM portal access so submissions and queries move without a middleman delay
- Ready to act as Product Registration Holder (PRH) with dealer’s license infrastructure in place
What we own for you
Strategy before spend
We map HSA pathways against your data package so you know whether full, abridged, or verification evaluation is the fastest credible route.
CTD / eCTD that survives review
Dossiers are assembled for HSA evaluation, with GDP inspection readiness built in—not bolted on after a deficiency letter.
MAH / PRH on the ground
We act as Marketing Authorization Holder and local pharmacovigilance contact, answering HSA queries in the language of the agency.
Labels that clear the first time
Package inserts, outer packs, and local language requirements are checked against current HSA rules before artwork freezes.
Intelligence that shortens cycles
Guideline watches and policy shifts are translated into concrete filing and variation actions for your product class.
Lifecycle after the certificate
Variations, adverse-event reporting, and post-market surveillance stay on one accountable desk through renewal.
Ready to hold the license
Therapeutic product, cosmetic, and device filings in Singapore require an ACRA-registered local company. We already hold the HSA dealer’s license needed to import and supply registered products to pharmacies, hospitals, and clinics—and trained consultants work daily in PRISM.
With systems live, we can step in as a dependable MAH or Product Registration Holder without a green-field setup project.
PRH responsibilities we run
As Product Registration Holder we stay accountable for the product’s full Singapore lifecycle.
01
File, vary, renew
Submit registration, variation, and renewal applications with complete dossiers and rapid responses to HSA queries.
02
Keep the label honest
Maintain labelling, packaging, and product information exactly as approved.
03
Watch safety continuously
Run pharmacovigilance, report ADRs on time, and deliver PBRER and other safety reports.
04
Surveil the market
Investigate complaints and quality defects; close the loop with HSA when needed.
05
Manage change
File formulation, site, and labelling changes before they go live.
06
Recall when required
Coordinate recalls with clear plans and progress reports to the Authority.
How HSA frames the market
Therapeutic products, biologics, and complementary health products follow distinct classification rules
Registration sits under the Health Products Act and HSA subsidiary regulations
Safety, efficacy, and quality gates apply before any local marketing begins
Module 1
Administrative information and application form.
Module 2
Overview and summaries of quality, safety, and efficacy data.
Modules 3, 4, and 5
Detailed data on quality, preclinical, and clinical studies.
Key points
Prepare a dossier in Common Technical Document (CTD) format or eCTD
Key modules include:
Only a locally registered company can act as the Product Registration Holder (PRH)
Foreign companies must appoint a Singapore-based PRH to manage product registration and post-approval obligations
Full Evaluation
For new products with no prior approvals.
Choosing the right HSA evaluation route
Singapore rewards good upstream data. If a trusted reference agency already knows your product, abridged or verification evaluation can compress timelines—provided classification, GMP evidence, and the local PRH story are airtight from day one.
Evaluation pathways
Abridged
- Prior approval by HSA-recognized authorities
- Dossier tailored to Singapore Module 1 needs
- Faster when the scientific core is already proven
Verification
- Identical dossier to a recognized approval
- Focus on sameness and administrative completeness
- Best for tightly controlled global packs
Full evaluation
- New products without prior recognized approval
- Deeper quality, nonclinical, and clinical review
- Plan buffer for queries and data requests
From classification to certificate
01
Classify with intent
Lock therapeutic product, CTGP, health supplement, traditional medicine, or CPM status before the dossier is built.
02
Appoint the local PRH
Foreign manufacturers name a Singapore legal entity to hold the registration and speak with HSA.
03
Submit on the HSA portal
File the complete electronic dossier; keep GMP certificates and inspection reports ready.
04
Clear evaluation queries
Answer safety, quality, and efficacy questions quickly so the review clock stays honest.
05
Receive the registration number
Market legally in Singapore, then stay compliant through surveillance, ADR reporting, variations, and five-year renewal.
How PECAN.Solutions accelerates the path
Pre-market feasibility and pathway design
Regulatory intelligence and gap analysis
GMP advisory and inspection support
Dossier preparation and PRISM submission
Local entity / PRH holding and import licensing
Lifecycle PV, variations, and PRH transfers
Ad-hoc regulatory consultation when timelines tighten
Ready when you are
Timelines and fees change—always confirm against the official HSA site. When you want a partner who already lives in that system, we are ready to open the consultation and move your product toward patients with confidence.
Our team documents assumptions, authority expectations, and decision points so sponsors can approve the plan with clear risk ownership.
Local pharmacists and regulatory specialists stay accountable through query cycles, inspection readiness, and post-approval obligations.
We align labeling, Module 1 localization, and partner communications so commercial launch can follow approval without rework.
Where pathways differ by product class, we sequence filings to protect the critical path and avoid avoidable deficiency letters.
Engagements can scale from a single dossier workstream to a multi-country virtual regulatory function.
PECAN.Solutions scopes each workstream with milestones, document owners, and authority touchpoints so registration, license holding, and commercial access stay on one plan.
Our team documents assumptions, authority expectations, and decision points so sponsors can approve the plan with clear risk ownership.
Local pharmacists and regulatory specialists stay accountable through query cycles, inspection readiness, and post-approval obligations.
Engagement notes
- We align labeling, Module 1 localization, and partner communications so commercial launch can follow approval without rework
- Where pathways differ by product class, we sequence filings to protect the critical path and avoid avoidable deficiency letters
- Engagements can scale from a single dossier workstream to a multi-country virtual regulatory function
- PECAN.Solutions scopes each workstream with milestones, document owners, and authority touchpoints so registration, license holding, and commercial access stay on one plan
- Our team documents assumptions, authority expectations, and decision points so sponsors can approve the plan with clear risk ownership
- Local pharmacists and regulatory specialists stay accountable through query cycles, inspection readiness, and post-approval obligations
- We align labeling, Module 1 localization, and partner communications so commercial launch can follow approval without rework
- Where pathways differ by product class, we sequence filings to protect the critical path and avoid avoidable deficiency letters
Engagement notes
- Engagements can scale from a single dossier workstream to a multi-country virtual regulatory function